Literature DB >> 15843149

GRIP1 mediates the interaction between the amino- and carboxyl-termini of the androgen receptor.

Howard C Shen1, Grant Buchanan, Lisa M Butler, Jennifer Prescott, Michael Henderson, Wayne D Tilley, Gerhard A Coetzee.   

Abstract

The androgen receptor (AR) mediates transactivation of target genes by acting as a dimer in which its amino-terminal domain (AR-NTD) interacts with its carboxyl-terminal, ligand-binding domain (AR-LBD) (N/C interaction). Here we assessed if and how AR N/C interaction relates to AR transactivation activity and how the p160 coactivator GRIP1 participates in both processes. The concentration of dihydrotestosterone needed for half-maximal N/C interaction was approximately 10-fold higher than for half-maximal transactivation, indicating a disparity between the two processes. Although a mutation of an LXXLL-like motif, 23 FQNLF 27 --> 23 FQNAA 27 , in the AR-NTD abolished AR N/C interaction, it could be restored by the co-expression of the coactivator GRIP1. Co-expression of mutated forms of GRIP1, possessing alterations known to abolish either of the two AR interaction domains, could not restore AR N/C interaction, suggesting that wild-type GRIP1 normally bridges the two AR domains. Although AR transactivation activity can proceed without AR N/C interaction, we propose that part of the GRIP1 coactivation activity resides in its ability to bind both AR-NTD and -LBD, to stabilize the N/C complex and allow for secondary cofactors to be recruited more efficiently. Our results also indicate that AR N/C interaction enhances but is not necessary for AR transactivation activity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15843149     DOI: 10.1515/BC.2005.009

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  13 in total

Review 1.  Allosteric modulators of steroid hormone receptors: structural dynamics and gene regulation.

Authors:  Raj Kumar; Iain J McEwan
Journal:  Endocr Rev       Date:  2012-03-20       Impact factor: 19.871

2.  Targeted disruption of the p160 coactivator interface of androgen receptor (AR) selectively inhibits AR activity in both androgen-dependent and castration-resistant AR-expressing prostate cancer cells.

Authors:  Manjula Nakka; Irina U Agoulnik; Nancy L Weigel
Journal:  Int J Biochem Cell Biol       Date:  2012-12-25       Impact factor: 5.085

3.  Corepressor effect on androgen receptor activity varies with the length of the CAG encoded polyglutamine repeat and is dependent on receptor/corepressor ratio in prostate cancer cells.

Authors:  Grant Buchanan; Eleanor F Need; Jeffrey M Barrett; Tina Bianco-Miotto; Vanessa C Thompson; Lisa M Butler; Villis R Marshall; Wayne D Tilley; Gerhard A Coetzee
Journal:  Mol Cell Endocrinol       Date:  2011-06-01       Impact factor: 4.102

4.  An interdomain interaction of the androgen receptor is required for its aggregation and toxicity in spinal and bulbar muscular atrophy.

Authors:  Christopher R Orr; Heather L Montie; Yuhong Liu; Elena Bolzoni; Shannon C Jenkins; Elizabeth M Wilson; James D Joseph; Donald P McDonnell; Diane E Merry
Journal:  J Biol Chem       Date:  2010-09-08       Impact factor: 5.157

5.  FoxO1 mediates PTEN suppression of androgen receptor N- and C-terminal interactions and coactivator recruitment.

Authors:  Qiuping Ma; Wei Fu; Pengfei Li; Santo V Nicosia; Guido Jenster; Xiaohong Zhang; Wenlong Bai
Journal:  Mol Endocrinol       Date:  2008-12-12

6.  A novel androgen receptor amino terminal region reveals two classes of amino/carboxyl interaction-deficient variants with divergent capacity to activate responsive sites in chromatin.

Authors:  Eleanor F Need; Howard I Scher; Amelia A Peters; Nicole L Moore; Albert Cheong; Charles J Ryan; Gary A Wittert; Villis R Marshall; Wayne D Tilley; Grant Buchanan
Journal:  Endocrinology       Date:  2009-03-12       Impact factor: 4.736

7.  The cell fate determination factor dachshund inhibits androgen receptor signaling and prostate cancer cellular growth.

Authors:  Kongming Wu; Sanjay Katiyar; Agnes Witkiewicz; Anping Li; Peter McCue; Liang-Nian Song; Lifeng Tian; Ming Jin; Richard G Pestell
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

8.  Inhibition of androgen receptor transcriptional activity as a novel mechanism of action of arsenic.

Authors:  Adena E Rosenblatt; Kerry L Burnstein
Journal:  Mol Endocrinol       Date:  2009-01-08

9.  Sirtuin 1 is required for antagonist-induced transcriptional repression of androgen-responsive genes by the androgen receptor.

Authors:  Yan Dai; Duyen Ngo; Lora W Forman; David C Qin; Johanna Jacob; Douglas V Faller
Journal:  Mol Endocrinol       Date:  2007-05-15

10.  The chicken ovalbumin upstream promoter-transcription factor II negatively regulates the transactivation of androgen receptor in prostate cancer cells.

Authors:  Chin-Hee Song; Hyun Joo Lee; Eunsook Park; Keesook Lee
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.